BioCentury | Dec 15, 2020
Product Development

Dec. 14 COVID roundup: Phase III miss for Incyte-Novartis JAK inhibitor; Queensland vaccine program axed; plus Sputnik V final efficacy and Phase II starts for CureVac and Inovio

...Inc. (NASDAQ:GILD). NIH published the data Friday in The New England Journal of Medicine.Anti-HIV antibodies nix...
BioCentury | Feb 22, 2019
Company News

NICE nixes BioMarin's ultra-orphan therapy for lack of long-term data

The U.K.'s NICE did not recommend Brineura cerliponase alfa from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) due to uncertainty around the therapy's long-term efficacy and concerns NHS would be unable to implement the rare disease biotech's proposed...
BioCentury | Apr 20, 2018
Company News

Brazil nixes Soliris patent, says more could follow

A Brazilian court unanimously ruled Friday to remove patent protection for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), opening the door for production of biosimilar versions in the country. In a statement, Brazil’s Attorney General...
BioCentury | Apr 20, 2018

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
BioCentury | Sep 5, 2016

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | May 26, 2016
Targets & Mechanisms

Dissociating ketamine

For decades, researchers have struggled with the conundrum of how to exploit the antidepressant effects of ketamine without incurring its psychedelic effects. Now, a group from NIH and the University of Maryland has shown that...
BioCentury | May 18, 2015
Clinical News

PA-824: Phase III started

...Not-for-profit TB Alliance began the open-label, South African Phase III Nix-TB trial to evaluate the all-oral...
BioCentury | May 4, 2015
Emerging Company Profile

Nixing Niemann-Pick

Vtesse Inc. is hoping to change the course of disease in Niemann-Pick type C, a fatal ultra-Orphan lysosomal storage disorder, using a compound plucked from NIH's Therapeutics for Rare and Neglected Diseases repurposing project. Niemann-Pick...
BioCentury | Mar 5, 2015
Tools & Techniques

Nixing antibody aggregation

Australian newco Solvanix Pty. Ltd. was founded last month on the basis of two amino acid changes in an antibody. The start-up expanded its early studies showing the altered residues transformed a misbehaving mAb into...
BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3)

Cardiovascular disease INDICATION: Organ damage In vitro and mouse studies suggest BNIP3 antagonists could help prevent doxorubicin-induced cardiotoxicity. In mouse prenatal cardiac myocytes, the generic chemotherapeutic doxorubicin increased BNIP3 mRNA and protein levels, induced mitochondrial...
Items per page:
1 - 10 of 33